Insmed Inc Stock Today
| INSM Stock | USD 73.15 0.66 0.89% |
Performance0 of 100
| Odds Of DistressLess than 34
|
Insmed is selling at 73.15 as of the 24th of November 2024; that is 0.89 percent decrease since the beginning of the trading day. The stock's lowest day price was 72.94. Insmed has about a 34 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Insmed Inc's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of June 2000 | Category Healthcare | Classification Health Care |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. Insmed operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 178.9 M outstanding shares of which 13.85 M shares are currently shorted by private and institutional investors with about 11.79 trading days to cover. More on Insmed Inc
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Insmed Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | MBA JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInsmed can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Insmed's financial leverage. It provides some insight into what part of Insmed's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Insmed Inc (INSM) is traded on NASDAQ Exchange in USA. It is located in 700 US Highway 202/206, Bridgewater, NJ, United States, 08807 and employs 912 people. Insmed is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 13.09 B. Insmed Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 178.9 M outstanding shares of which 13.85 M shares are currently shorted by private and institutional investors with about 11.79 trading days to cover.
Insmed Inc currently holds about 554.87 M in cash with (536.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62.
Check Insmed Probability Of Bankruptcy
Ownership AllocationThe majority of Insmed Inc outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Insmed to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Insmed Inc. Please pay attention to any change in the institutional holdings of Insmed Inc as this could imply that something significant has changed or is about to change at the company. On July 9, 2024, Representative Josh Gottheimer of US Congress acquired under $15k worth of Insmed Inc's common stock.
Check Insmed Ownership Details
Insmed Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Artisan Partners Limited Partnership | 2024-09-30 | 2.9 M | |
| Macquarie Group Ltd | 2024-06-30 | 2.7 M | |
| Franklin Resources Inc | 2024-09-30 | 2.7 M | |
| Ameriprise Financial Inc | 2024-06-30 | 2.5 M | |
| Suvretta Capital Management, Llc | 2024-06-30 | 2.5 M | |
| Alliancebernstein L.p. | 2024-06-30 | 2.5 M | |
| William Blair Investment Management, Llc | 2024-09-30 | 2.4 M | |
| T. Rowe Price Investment Management,inc. | 2024-09-30 | 2.3 M | |
| Hhg Plc | 2024-06-30 | 2.1 M | |
| Vanguard Group Inc | 2024-09-30 | 17.1 M | |
| Blackrock Inc | 2024-06-30 | 14.3 M |
Insmed Historical Income Statement
Insmed Stock Against Markets
Insmed Corporate Management
| Mandy Fahey | Executive Communications | Profile | |
| Sara MBA | Chief Officer | Profile | |
| Nicole MBA | Chief Officer | Profile | |
| John Wise | Head VP | Profile | |
| Eleanor Barisser | Associate Relations | Profile | |
| MD MBA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.